206 related articles for article (PubMed ID: 7621440)
21. Review article: The role of oncogenes, tumour suppressor genes and growth factors in oral squamous cell carcinoma: a case of apoptosis versus proliferation.
Sugerman PB; Joseph BK; Savage NW
Oral Dis; 1995 Sep; 1(3):172-88. PubMed ID: 8705824
[TBL] [Abstract][Full Text] [Related]
22. Bcl-2 is an apoptotic target suppressed by both c-Myc and E2F-1.
Eischen CM; Packham G; Nip J; Fee BE; Hiebert SW; Zambetti GP; Cleveland JL
Oncogene; 2001 Oct; 20(48):6983-93. PubMed ID: 11704823
[TBL] [Abstract][Full Text] [Related]
23. Disruption of the ARF-Mdm2-p53 tumor suppressor pathway in Myc-induced lymphomagenesis.
Eischen CM; Weber JD; Roussel MF; Sherr CJ; Cleveland JL
Genes Dev; 1999 Oct; 13(20):2658-69. PubMed ID: 10541552
[TBL] [Abstract][Full Text] [Related]
24. Sensitivity to myc-induced apoptosis is retained in spontaneous and transplanted lymphomas of CD2-mycER mice.
Blyth K; Stewart M; Bell M; James C; Evan G; Neil JC; Cameron ER
Oncogene; 2000 Feb; 19(6):773-82. PubMed ID: 10698495
[TBL] [Abstract][Full Text] [Related]
25. Reactive oxygen species and the regulation of cell death by the Bcl-2 gene family.
Korsmeyer SJ; Yin XM; Oltvai ZN; Veis-Novack DJ; Linette GP
Biochim Biophys Acta; 1995 May; 1271(1):63-6. PubMed ID: 7599227
[TBL] [Abstract][Full Text] [Related]
26. Prostate-specific expression of p53(R172L) differentially regulates p21, Bax, and mdm2 to inhibit prostate cancer progression and prolong survival.
Hernandez I; Maddison LA; Wei Y; DeMayo F; Petras T; Li B; Gingrich JR; Rosen JM; Greenberg NM
Mol Cancer Res; 2003 Dec; 1(14):1036-47. PubMed ID: 14707287
[TBL] [Abstract][Full Text] [Related]
27. Wild-type p53-triggered apoptosis is inhibited by bcl-2 in a v-myc-induced T-cell lymphoma line.
Wang Y; Szekely L; Okan I; Klein G; Wiman KG
Oncogene; 1993 Dec; 8(12):3427-31. PubMed ID: 8247547
[TBL] [Abstract][Full Text] [Related]
28. Bcl-2 is a better therapeutic target than c-Myc, but attacking both could be a more effective treatment strategy for B-cell lymphoma with concurrent Bcl-2 and c-Myc overexpression.
Sasaki N; Kuroda J; Nagoshi H; Yamamoto M; Kobayashi S; Tsutsumi Y; Kobayashi T; Shimura Y; Matsumoto Y; Taki T; Nishida K; Horiike S; Akao Y; Taniwaki M
Exp Hematol; 2011 Aug; 39(8):817-28.e1. PubMed ID: 21640157
[TBL] [Abstract][Full Text] [Related]
29. Concurrent activation of MYC and BCL2 in B cell non-Hodgkin lymphoma cell lines by translocation of both oncogenes to the same immunoglobulin heavy chain locus.
Dyer MJ; Lillington DM; Bastard C; Tilly H; Lens D; Heward JM; Stranks G; Morilla R; Monrad S; Guglielmi P; Kluin-Nelemans JC; Hagemeijer A; Young BD; Catovsky D
Leukemia; 1996 Jul; 10(7):1198-208. PubMed ID: 8684002
[TBL] [Abstract][Full Text] [Related]
30. Bcl-2 family proteins and the regulation of programmed cell death in leukemia and lymphoma.
Reed JC; Miyashita T; Krajewski S; Takayama S; Aime-Sempe C; Kitada S; Sato T; Wang HG; Harigai M; Hanada M; Krajewska M; Kochel K; Millan J; Kobayashi H
Cancer Treat Res; 1996; 84():31-72. PubMed ID: 8724625
[No Abstract] [Full Text] [Related]
31. The BCL6 proto-oncogene: a leading role during germinal center development and lymphomagenesis.
Jardin F; Ruminy P; Bastard C; Tilly H
Pathol Biol (Paris); 2007 Feb; 55(1):73-83. PubMed ID: 16815642
[TBL] [Abstract][Full Text] [Related]
32. The immunoglobulin heavy-chain gene 3' enhancers deregulate bcl-2 promoter usage in t(14;18) lymphoma cells.
Duan H; Heckman CA; Boxer LM
Oncogene; 2007 Apr; 26(18):2635-41. PubMed ID: 17043638
[TBL] [Abstract][Full Text] [Related]
33. Bcl-2/Bax: a rheostat that regulates an anti-oxidant pathway and cell death.
Korsmeyer SJ; Shutter JR; Veis DJ; Merry DE; Oltvai ZN
Semin Cancer Biol; 1993 Dec; 4(6):327-32. PubMed ID: 8142617
[TBL] [Abstract][Full Text] [Related]
34. Mdm2 haplo-insufficiency profoundly inhibits Myc-induced lymphomagenesis.
Alt JR; Greiner TC; Cleveland JL; Eischen CM
EMBO J; 2003 Mar; 22(6):1442-50. PubMed ID: 12628936
[TBL] [Abstract][Full Text] [Related]
35. Combined loss of PUMA and p21 accelerates c-MYC-driven lymphoma development considerably less than loss of one allele of p53.
Valente LJ; Grabow S; Vandenberg CJ; Strasser A; Janic A
Oncogene; 2016 Jul; 35(29):3866-71. PubMed ID: 26640149
[TBL] [Abstract][Full Text] [Related]
36. Control of apoptosis in hematopoiesis and leukemia by cytokines, tumor suppressor and oncogenes.
Lotem J; Sachs L
Leukemia; 1996 Jun; 10(6):925-31. PubMed ID: 8667646
[TBL] [Abstract][Full Text] [Related]
37. Genetic analysis of Raf1, Mdm2, c-Myc, Cdc25a and Cdc25b proto-oncogenes in 2',3'-dideoxycytidine- and 1,3-butadiene-induced lymphomas in B6C3F1 mice.
Zhuang S; Söderkvist P
Mutat Res; 2000 Jul; 452(1):19-26. PubMed ID: 10894886
[TBL] [Abstract][Full Text] [Related]
38. Analysis of BCL2 and MYC expression in non-Hodgkin's lymphomas by in situ hybridization: correlation with chromosome translocations.
Murty VV; Ladanyi M; Houldsworth J; Mikraki V; Chaganti RS
Diagn Mol Pathol; 1992 Dec; 1(4):221-8. PubMed ID: 1342969
[TBL] [Abstract][Full Text] [Related]
39. Bax regulates c-Myc-induced mammary tumour apoptosis but not proliferation in MMTV-c-myc transgenic mice.
Jamerson MH; Johnson MD; Korsmeyer SJ; Furth PA; Dickson RB
Br J Cancer; 2004 Oct; 91(7):1372-9. PubMed ID: 15354213
[TBL] [Abstract][Full Text] [Related]
40. Molecular pathogenesis of non-Hodgkin lymphoma: a clinical perspective.
Gaidano G; Pastore C; Volpe G
Haematologica; 1995; 80(5):454-72. PubMed ID: 8566891
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
